Monthly Prescribing Reference

Venclexta Labeling Updated With Minimal Residual Disease Negativity Data

The Food and Drug Administration (FDA) has updated the labeling for Venclexta (venetoclax; AbbVie and Genentech) in combination with rituximab to include data about patients with previously-treated ...
Nasdaq

AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia

AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase ...
PharmiWeb

FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...
KRON4 News

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...